Home > Publications database > Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis. > print

001     301906
005     20250610113541.0
024 7 _ |a 10.1016/j.ygyno.2025.05.013
|2 doi
024 7 _ |a pmid:40482607
|2 pmid
024 7 _ |a 0090-8258
|2 ISSN
024 7 _ |a 1095-6859
|2 ISSN
037 _ _ |a DKFZ-2025-01176
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Fu, Zhuxuan
|b 0
245 _ _ |a Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
260 _ _ |a Orlando, Fla.
|c 2025
|b Academic Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1749542049_29235
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Many epithelial ovarian cancer (EOC) risk factors relate to sex hormones. The association between these factors and the expression of androgen receptor (AR), estrogen receptor-α (ER), and progesterone receptor (PR) in tumors is unknown.We linked epidemiologic, AR/ER/PR tumor expression, and survival data from 19 studies in the Ovarian Cancer Association Consortium (OCAC; 4762 cases, 20,888 controls) and the Ovarian Tumor Tissue Analysis (OTTA) consortium (5737 cases). We estimated odds ratios (ORs) and 95 % confidence intervals (CIs) between hormonally-linked factors and tumor AR/ER/PR expression using polytomous logistic regression. We assessed survival by AR/ER/PR tumor expression overall and by histotype using Kaplan-Meier curves and Cox proportional hazards models.Overweight/obesity was associated with higher risk of ER- tumors (OR:1.53, 95 % I:1.18-1.98). Hysterectomy was associated with greater risk of ER+ tumors (OR:4.99, 95 % CI:4.27-5.83), which varied by AR expression (Pheter=0.003). Postmenopause was associated with a higher risk of PR- tumors (OR 1.52, 95 % CI 1.26-1.83), which varied based by AR (Pheter < 0.001) and ER (Pheter < 0.001) expression. Gravidity, oral contraception duration, and breastfeeding duration showed differing dose-response relationships according to AR/ER/PR expression. Hormone therapy use, postmenopause, physical inactivity, and being obese/overweight prior to diagnosis were differentially associated with survival based on AR/ER/PR expression and histotype.EOC has varying risk and prognostic profiles depending on both histotype and AR/ER/PR expression. Biological mechanisms underlying the association between hormonally-linked factors and EOC need to be studied by both histotypes and by AR, ER, and PR expression.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Epithelial ovarian cancer
|2 Other
650 _ 7 |a Hormonal factors
|2 Other
650 _ 7 |a Hormone receptor
|2 Other
650 _ 7 |a Risk
|2 Other
650 _ 7 |a Survival
|2 Other
650 _ 7 |a androgen receptor
|2 Other
650 _ 7 |a estrogen receptor
|2 Other
650 _ 7 |a progesterone receptor
|2 Other
700 1 _ |a Borho, Lauren
|b 1
700 1 _ |a Taylor, Sarah E
|b 2
700 1 _ |a Kelemen, Linda E
|b 3
700 1 _ |a DeFazio, Anna
|b 4
700 1 _ |a Webb, Penelope M
|b 5
700 1 _ |a Köbel, Martin
|b 6
700 1 _ |a Meagher, Nicola S
|b 7
700 1 _ |a Na, Renhua
|b 8
700 1 _ |a Antoniou, Antonis C
|b 9
700 1 _ |a Brand, Alison H
|b 10
700 1 _ |a Kennedy, Catherine J
|b 11
700 1 _ |a Nevins, Nikilyn
|b 12
700 1 _ |a Pharoah, Paul D P
|b 13
700 1 _ |a Shvetsov, Yurii B
|b 14
700 1 _ |a Winham, Stacey J
|b 15
700 1 _ |a Alsop, Jennifer
|b 16
700 1 _ |a Beckmann, Matthias W
|b 17
700 1 _ |a Bolithon, Adelyn
|b 18
700 1 _ |a Boros, Jessica
|b 19
700 1 _ |a Bowtell, David D L
|b 20
700 1 _ |a Brenton, James D
|b 21
700 1 _ |a Carney, Michael E
|b 22
700 1 _ |a Chudecka-Głaz, Anita
|b 23
700 1 _ |a Cook, Linda S
|b 24
700 1 _ |a Cybulski, Cezary
|b 25
700 1 _ |a Fasching, Peter A
|b 26
700 1 _ |a Fereday, Sian
|b 27
700 1 _ |a Fortner, Renée T
|0 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
|b 28
|u dkfz
700 1 _ |a García, María J
|b 29
700 1 _ |a Goode, Ellen L
|b 30
700 1 _ |a Goodman, Marc T
|b 31
700 1 _ |a Gronwald, Jacek
|b 32
700 1 _ |a Hartmann, Arndt
|b 33
700 1 _ |a Hernandez, Brenda Y
|b 34
700 1 _ |a Høgdall, Estrid
|b 35
700 1 _ |a Huntsman, David G
|b 36
700 1 _ |a Jensen, Allan
|b 37
700 1 _ |a Jimenez-Linan, Mercedes
|b 38
700 1 _ |a Joseph, Janine M
|b 39
700 1 _ |a Karlan, Beth Y
|b 40
700 1 _ |a Kaznowska, Ewa
|b 41
700 1 _ |a Kjaer, Susanne K
|b 42
700 1 _ |a Kluz, Tomasz
|b 43
700 1 _ |a Koziak, Jennifer M
|b 44
700 1 _ |a Lester, Jenny
|b 45
700 1 _ |a Longacre, Teri A
|b 46
700 1 _ |a Lycke, Maria
|b 47
700 1 _ |a McGuire, Valerie
|b 48
700 1 _ |a Moysich, Kirsten B
|b 49
700 1 _ |a Murphy, Rachel A
|b 50
700 1 _ |a Orsulic, Sandra
|b 51
700 1 _ |a Ramus, Susan J
|b 52
700 1 _ |a Rodríguez-Antona, Cristina
|b 53
700 1 _ |a Rothstein, Joseph H
|b 54
700 1 _ |a Samra, Spinder
|b 55
700 1 _ |a Sieh, Weiva
|b 56
700 1 _ |a Steed, Helen
|b 57
700 1 _ |a Sundfeldt, Karin
|b 58
700 1 _ |a Talhouk, Aline
|b 59
700 1 _ |a Uciński, Jan
|b 60
700 1 _ |a Wang, Chen
|b 61
700 1 _ |a Wentzensen, Nicolas
|b 62
700 1 _ |a Whittemore, Alice S
|b 63
700 1 _ |a Wilkens, Lynne R
|b 64
700 1 _ |a Songer, Thomas
|b 65
700 1 _ |a Brooks, Maria Mori
|b 66
700 1 _ |a Tang, Lu
|b 67
700 1 _ |a Modugno, Francesmary
|b 68
773 _ _ |a 10.1016/j.ygyno.2025.05.013
|g Vol. 198, p. 112 - 129
|0 PERI:(DE-600)1467974-7
|p 112 - 129
|t Gynecologic oncology
|v 198
|y 2025
|x 0090-8258
909 C O |o oai:inrepo02.dkfz.de:301906
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-01
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b GYNECOL ONCOL : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-01
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-01
920 1 _ |0 I:(DE-He78)C180-20160331
|k C180
|l Krebsepidemiologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C180-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21